Here is Eli Lilly’s competitive edge in GLP-1 obesity drugs and Abbott’s secondary play

Health, Fitness & Food

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. (We’re no longer recording the audio, so we can get this new written feature to members as quickly as possible.)

Products You May Like

Articles You May Like

Healthy Returns: Novo Nordisk’s Ozempic faces scrutiny over potential link to rare eye condition
Dexcom’s over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Baked Salmon
I Tried Khloé Kardashian’s Glitter Compression Catsuit at a Solidcore Class
These Dancers Want to Prove Breaking Isn’t a Joke After the Olympics Memes

Leave a Reply

Your email address will not be published. Required fields are marked *